Navigation Links
PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
Date:9/21/2010

SOUTH PLAINFIELD, N.J., Sept. 21 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF).  The goal of the FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO)

"We are pleased to receive this grant from the FDA to support our ongoing development of ataluren for the treatment of nonsense mutation cystic fibrosis," stated Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics.  "In addition to recognizing the potential of ataluren, this grant reflects PTC's long-standing commitment to developing new treatments for patients with rare genetic disorders that severely impact survival and quality of life."

The Phase 3 trial will enroll approximately 200 patients at research centers in North America, Europe and Israel.  The primary goal of the study is to evaluate whether ataluren can improve lung function as measured by forced expiratory volume (FEV1).  Other outcome measures will evaluate whether ataluren can decrease lung infections, reduce the frequency of cough and improve patient-reported quality of life.  Patients are randomized to receive either ataluren (40 mg/kg) or placebo daily for 48 weeks.  Study candidates include patients who are at least six years of age and have CF due to a nonsense mutation.

Patients with CF lack adequate levels of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride channel necessary for norm
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused on ... of tumor cells in the bloodstream, today announced that ... support application powered by CollabRx, Inc. , Available ... Therapy Finder will provide breast cancer patients and their ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... 21, 2009) A faster tool for cell programming and ... have won grand prizes of the 2009 Collegiate Inventors Competition, ... by the Abbott Fund, the non-profit foundation of the global ... Trademark Office (USPTO). Harris Wang, who invented a new ...
... Myriant Technologies LLC (Myriant), a privately-held, biotech developer ... of its Science Advisory Board and the appointment ... collectively will provide broad insight into all aspects ... biomass feedstocks into valuable chemicals. , (Logo: ...
... N.J. and WALTHAM, Mass., Oct. 21 BioWa, ... today that they have entered into an agreement ... POTELLIGENT(®) Technology platform for the development of antibody-dependent ... grants NKTT non-exclusive rights to research, develop, manufacture ...
Cached Biology Technology:Winners announced in 2009 Collegiate Inventors Competition 2Winners announced in 2009 Collegiate Inventors Competition 3Winners announced in 2009 Collegiate Inventors Competition 4Winners announced in 2009 Collegiate Inventors Competition 5Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 2Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 3BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 2BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 3
(Date:4/23/2014)... has transformed the energy landscape in the U.S., ... conflict among the energy industry, residents and agricultural ... add that degraded water quality is a potential ... article appears in the ACS journal Environmental ... and colleagues point out that a major criticism ...
(Date:4/23/2014)... the family of bacteria that causes whooping cough ... surprising findings about the bacteria,s origin and evolution. ... to control this respiratory disease, which kills 195,000 ... 343 strains of the Bordetella pertussis ... last 100 years illustrates how vaccination has shaped ...
(Date:4/23/2014)... quickly. It involves visual searching for clues to ... Similarly to humans, biological systems are sometimes under ... that need to be read quickly are usually ... easier it will be to read them quickly. ... Portugal) and Centre for Molecular and Structural Biomedicine ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Impact of whooping cough vaccination revealed 2Cell division speed influences gene architecture 2
... is nicknamed "yellowcake" for its color and powdered consistency. ... , The yellow monster surfaced on the Navajo Nation ... continued for the next several decades. In its aftermath ... and worries about environmental contamination among people who live ...
... one day precisely release drugs and vaccines inside the ... study, by researchers at Ghent University and the Universit? ... Jan. 9, 2006, print issue of the American Chemical ... other microcapsules, which release their drug cargo only when ...
... study is being published in an advance online version of ... XPB helicase from an archaea, a single cell organism similar ... strands of the nucleic acid double helix, an action that ... well as other cell processes. , "XPB was initially ...
Cached Biology News:Study may help slay 'Yellow Monster' 2Study may help slay 'Yellow Monster' 3Enzyme crystal structure reveals 'unexpected' genome repair functions 2